Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

32.97USD
4:00pm EDT
Change (% chg)

$-0.79 (-2.34%)
Prev Close
$33.76
Open
$33.70
Day's High
$33.79
Day's Low
$32.64
Volume
123,839
Avg. Vol
423,242
52-wk High
$48.20
52-wk Low
$9.40

Select another date:

Thu, May 4 2017

BRIEF-Esperion reports Q1 net loss per common share $1.80

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results

BRIEF-Boxer Capital reports 5.3 pct passive stake in Esperion Therapeutics

* Boxer Capital LLC reports 5.3 percent passive stake in Esperion Therapeutics Inc as of March 20 - SEC filing Source: (http://bit.ly/2mZu8Mb) Further company coverage:

BRIEF-Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid

* Esperion announces fda confirmation regarding regulatory pathway to approval for an ldl-c lowering indication for bempedoic acid

BRIEF-Esperion initiates of phase 2 triplet oral therapy study

* Esperion announces initiation of phase 2 triplet oral therapy study of bempedoic acid/ezetimibe/atorvastatin

BRIEF-Esperion posts Q4 loss per share $1.29

* Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results

BRIEF-Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of Bempedoic Acid

* Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of bempedoic acid in patients with hypercholesterolemia

Select another date:

More From Around the Web